VRDN – viridian therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target lowered by analysts at HC Wainwright from $37.00 to $27.00. They now have a "buy" rating on the stock.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $36.00 to $31.00. They now have an "outperform" rating on the stock.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) was downgraded by analysts at LADENBURG THALM/SH SH from a "buy" rating to a "neutral" rating.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $30.00 price target on the stock.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) was downgraded by analysts at B. Riley from a "buy" rating to a "neutral" rating. They now have a $20.00 price target on the stock, down previously from $25.00.
Form 10-Q Viridian Therapeutics, For: Mar 31
Form 8-K Viridian Therapeutics, For: May 08
Form ARS Viridian Therapeutics, For: Dec 31
Form DEFA14A Viridian Therapeutics,
Form DEF 14A Viridian Therapeutics, For: Jun 17
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.